Top

Published in:

01-12-2016 | Case Report

Bilateral periprosthetic joint infection with Ureaplasma urealyticum in an immunocompromised patient

Authors: R. L. Roerdink, C. M. Douw, A. C. A. P. Leenders, R. S. Dekker, M. Dietvorst, C. J. M. Oosterbos, H. T. J. Roerdink, R. W. T. M. Kempen, L. P. A. Bom

Published in: Infection | Issue 6/2016

Abstract

This case study discusses how we diagnosed and treated a patient with a late haematogenous bilateral periprosthetic joint infection (PJI) after total knee arthroplasties caused by Ureaplasma urealyticum. This has never been reported before. We will discuss how we used a PET-CT, synovial fluid cell count, and synovial fluid analysis by 16S rRNA gene sequencing to diagnose this PJI. We will also discuss how we treated this patient to obtain full recovery.

Huotari K, Peltola M, Jämsen E. The incidence of late prosthetic joint infections: a registry-based study of 112,708 primary hip and knee replacements. Acta Orthop. 2015;86:321–5.CrossRefPubMedPubMedCentral

Gundtoft PH, Overgaard S, Schønheyder HC, Møller JK, Kjærsgaard-Andersen P, Pedersen AB. The “true” incidence of surgically treated deep prosthetic joint infection after 32,896 primary total hip arthroplasties: a prospective cohort study. Acta Orthop. 2015;86:326–34.CrossRefPubMedPubMedCentral

J Parvizi, T Gehrke. In: Proceedings of the International Consensus Meeting on Periprosthetic Joint Infection. 2013. ISBN 978-1-57400-147-1.

Kumar R, Kumar V, Malhotra R. Potential clinical implication of 18 F-FDG PET/CT in diagnosis of periprosthetic infection and its comparison with 18 F-Fluoride PET/CT. J Med Imaging Radiat Oncol. 2016. doi:10.1111/1754-9485.12444 (Epub ahead of print).

Basu S, Kwee TC, Saboury B, Garino JP, Nelson CL, Zhuang H, et al. FDG PET for diagnosing infection in hip and knee prostheses: prospective study in 221 prostheses and subgroup comparison with combined (111)In-labeled leukocyte/(99 m)Tc-sulfur colloid bone marrow imaging in 88 prostheses. Clin Nucl Med. 2014;39:609–15.CrossRefPubMedPubMedCentral

Bedair H, Ting N, Jacovides C, Saxena A, Moric M, Parvizi J, Della Valle CJ. The Mark Coventry Award: diagnosis of early postoperative TKA infection using synovial fluid analysis. Clin Orthop Relat Res. 2011;469:34–40.CrossRefPubMed

Sköldenberg OG, Rysinska AD, Neander G, Muren OH, Ahl TE. Ureaplasma urealyticum infection in total hip arthroplasty leading to revision. J Arthroplasty. 2010;25:11–3.CrossRef

Dias JM, Costa MM, da Silva JAP, de Queiroz MV. Septic arthritis: patients with or without isolated infectious agents have similar characteristics. Infection. 2014;42:385–91.CrossRef

Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol. 2009;84:414–7.CrossRefPubMed

10.

Boxer L. How to approach neutropenia. Hematol Educ Progr Am Soc Hematol. 2012;2012:174–82.

11.

Presterl E, Grisold AJ, Reichmann S, Hirschl AM, Georgopoulos A, Graninger W. Viridans streptococci in endocarditis and neutropenic sepsis: biofilm formation and effects of antibiotics. J Antimicrob Chemother. 2005;55:45–50.CrossRefPubMed

12.

Tande A, Patel R. Prosthetic joint infection. Clin Microbiol Rev. 2014;27:302–45.CrossRefPubMedPubMedCentral

13.

Kado R, Sanders G, McCune WJ. Suppression of normal immune responses after treatment with rituximab. Curr Opin Rheumatol. 2016;28:251–8.CrossRefPubMed

14.

Filanovsky K, Miller EB, Sigler E, Berrebi A, Shvidel L. Incidence of profound hypogammaglobulinemia and infection rate in lymphoma patients following the combination of chemotherapy and rituximab. Recent Pat Anticancer Drug Discov. 2016;11:228–35.CrossRefPubMed

15.

Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22:396–414.CrossRefPubMedPubMedCentral

16.

Achermann Y, Stasch P, Preiss S, Lucke K, Vogt M. Characteristics and treatment outcomes of 69 cases with early prosthetic joint infections of the hip and knee. Infection. 2014;42:511–9.CrossRefPubMed

17.

Samra Z, Rosenberg S, Dan M. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin. J Chemother. 2011;23:77–9.CrossRefPubMed

Title: Bilateral periprosthetic joint infection with Ureaplasma urealyticum in an immunocompromised patient
Authors: R. L. Roerdink
C. M. Douw
A. C. A. P. Leenders
R. S. Dekker
M. Dietvorst
C. J. M. Oosterbos
H. T. J. Roerdink
R. W. T. M. Kempen
L. P. A. Bom
Publication date: 01-12-2016
Publisher: Springer Berlin Heidelberg
Published in: Infection / Issue 6/2016
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-016-0912-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Bilateral periprosthetic joint infection with Ureaplasma urealyticum in an immunocompromised patient

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Zika virus disease: a current review of the literature

Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C

Nosocomial candidemia in patients admitted to medicine wards compared to other wards: a multicentre study

Rapid molecular diagnosis of infective aortic valve endocarditis caused by Coxiella burnetii

Measles, mumps, rubella, and varicella seroprevalence in refugees in Germany in 2015

Carbapenem-resistant Lactobacillus intra-abdominal infection in a renal transplant recipient with a history of probiotic consumption

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page